Comparative Pharmacology
Head-to-head clinical analysis: LEVOFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus NOROXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER versus NOROXIN.
LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER vs NOROXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Levofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby inhibiting DNA replication and transcription.
Noroxin (norfloxacin) is a fluoroquinolone antibacterial agent that inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes required for bacterial DNA replication, transcription, repair, and recombination.
500 mg or 750 mg intravenously once daily. Infusion over 60-90 minutes.
400 mg orally twice daily for 3-14 days depending on indication.
None Documented
None Documented
6-8 hours in patients with normal renal function (creatinine clearance >50 mL/min); increases to 20-48 hours in severe renal impairment (CrCl <20 mL/min); clinically relevant for dosing interval adjustment.
Terminal elimination half-life is 6-7 hours in patients with normal renal function. Prolonged to 21-28 hours in severe renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal: ~87% of dose excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5% eliminated as unchanged drug and metabolites; <4% recovered in feces.
Renal excretion accounts for approximately 30% of the dose as unchanged drug. Biliary/fecal elimination is a major route, with about 60-70% recovered in feces as unchanged drug and metabolites.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic